BerGenBio

Share Issue/Capital Change • Jul 13, 2017

BerGenBio ASA: Share capital increase registered

Bergen, Norway, 13 July 2017.

Reference is made to the stock exchange notice published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 27 June 2017 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise options pursuant to the Company's employee share option program.The share capital increase has been duly registered in the Norwegian Register of Business Enterprises. Following such registration, the Company's share capital is NOK 4,975,720 divided into 49,757,200 shares, each with a nominal value of NOK 0.10.

For further information, please contact:

Richard Godfrey, Chief Executive Officer

Phone: +47 917 86 304

E-mail: media@bergenbio.com

About BerGenBio ASA

BerGenBio (Bergen, Norway) is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the central role of AXL kinase in promoting cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers.

BGB324, is a selective, potent and orally available small molecule AXL inhibitor in Phase II clinical development in four major cancer indications. It is the only selective oral AXL inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS) and in combination with TARCEVA® (erlotinib) in advanced non-small-cell lung cancer (NSCLC): and in combination with KEYTRUDA® (pembrolizumab) in advanced NSCLC and triple negative breast cancer (TNBC) in collaboration with MSD.

The Company is also developing a diversified pre-clinical pipeline of selective AXL inhibitors including BGB149, anti-AXL monoclonal antibody.

For further information, please visit: www.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.